A practical guide to the treatment of complicated skin and soft tissue infections

Drugs

Volumn 63, Issue 14, 2003, Pages 1459-1480

  Fung, Horatio B ^a,b   Chang, Joanne Y ^b   Kuczynski, Stephen ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOXITIN; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CLINAFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERTAPENEM; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; NAFCILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; SULTAMICILLIN; TEICOPLANIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ABSCESS DRAINAGE; ANTIBIOTIC THERAPY; BACILLUS; BETA HEMOLYTIC STREPTOCOCCUS; COMMUNICABLE DISEASE; COMORBIDITY; DEBRIDEMENT; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM STAINING; HEADACHE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; NAUSEA; PATHOGENESIS; PENICILLIN ALLERGY; PENICILLIN RESISTANCE; PHOTOSENSITIVITY DISORDER; PHYSICAL EXAMINATION; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; PRACTICE GUIDELINES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

BACILLI; BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 0038781167     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363140-00003     Document Type: Review

References (66)

1. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable diseases United States cumulative week ending 2000 Dec 30. MMWR Morb Mortal Wkly Rep 2001 Jan; 49: 1167
2. Centers for Disease Control and Prevention. Summary of provisional cases of selected notifiable diseases United States cumulative week ending 2001 Dec 29. MMWR Morb Mortal Wkly Rep 2002 Jan; 50: 1169
3. Hill MK, Sanders CV. Skin and soft tissue infections in critical care. Crit Care Clin 1998 Apr; 14: 251-62
4. File TM, Tan JS, Dipersio JR. Diagnosing and treating the flesh-eating bacteria syndrome. Cleve Clin J Med 1998 May; 65: 241-9
5. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999 May; 34: 65-72
6. Rybak MJ, Akins RL. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance. Drugs 2001; 61: 1-7
7. Hiramatsu K, Hanaki H, Yabuta K, et al. Methicillin-resistant Staphylococcus anmus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997 Jul; 40: 135-6
8. Sievert DM, Boulton ML, Stoltman G, et al. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002 Jul; 51: 565-7
9. Miller D, Urdaneta V, Weltman A. Public health dispatch: vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002 [letter]. MMWR Morb Mortal Wkly Rep 2002 Oct; 51: 902
10. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999 Sep; 44 Suppl. A: 19-23
11. Tan JS, Wishnow RM, Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind randomized multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother 1993 Aug; 37: 1580-6
12. Tassler H, Cullmann W, Elhardt D. Therapy of soft tissue infections with piperacillin/tazobactam. J Antimicrob Chemother 1993 Jan; 31 Suppl. A: 105-12
13. Center for Drug Evaluation and Research. Guidance for industry: uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment [online]. Available from URL: http://www.fda.gov/cder/guidance/2566dft.pdf [Accessed 2002 Nov 10]
14. Pankey G, Katner HP, Valainis GT, et al. Overview of bacterial infections of the skin and soft tissue and clinical experience with ticarcillin plus clavulanate potassium in their treatment. Am J Med 1985 Nov; 79 Suppl. B: 106-15
15. File TM, Tan JS. Treatment of skin and soft tissue infections. Am J Surg 1995 May; 169 Suppl. 5A: 27S-33S
16. Wasilewski MM, Wilson MG, Sides GD, et al. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J Antimicrob Chemother 2000 Aug; 46: 255-62
17. Brown G, Chamberlain R, Goulding J, et al. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996 Sep; 14: 547-51
18. Critchley IA, Sahm DF, Thornsberry C, et al. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis 2002 Feb; 42: 129-35
19. Demidovich CW, Wittler RR, Ruff ME, et al. Impetigo. Am J Dis Child 1990 Dec; 144: 1313-5
20. Daly JS, Worthington MG, Andrews RJ, et al. Randomized double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections. Antimicrob Agents Chemother 1990 Apr; 34: 654-6
21. Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust 1998 Nov; 169: 519-22
22. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2000 Dec; 29: 404-21
23. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison: Mississippi 2000. JAMA 2002 Jan; 287: 181-2
24. Feder HM. Methicillin-resistant Staphylococcus aureus infections in 2 pediatric outpatients. Arch Fam Med 2000 Jun; 9: 560-2
25. Sattler CA, Mason EO, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristic of community-acquired methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis 2002 Oct; 21: 910-7
26. Jones ME, Schmitz FJ, Fluit AC, et al. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programme. Eur J Clin Microbiol Infect Dis 1999 Jun; 18: 403-8
27. Gales AC, Jones RN, Pfaller MA, et al. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. Int J Infect Dis 2000; 4: 75-84
28. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994 May; 18: 683-93
29. Gentry LO. Therapy with newer oral β-lactam and quinolone agents for infections of the skin and skin structure: a review. Clin Infect Dis 1992 Jan; 14: 285-97
30. Gentry LO. Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother 1991 Dec; 28 Suppl. C: 97-110
31. Bergstein JM, Baker IV EJ, Aprahamian C, et al. Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology and treatment. Am Surg 1995 Dec; 61: 1105-8
32. Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 2001 Jul; 33: 35-40
33. Henriksen BM, Albrektsen SB, Simper LB, et al. Soft tissue infections from drug abuse: a clinical and microbiological review of 145 cases. Acta Orthop Scand 1994 Dec; 65: 625-8
34. Talan DA, Summanen PH, Finegold SM. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clin Infect Dis 2000 Aug; 31: 464-71
35. Summanen PH, Talan DA, Strong C, et al. Bacteriology of skin and soft tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 1995 Jan; 20 Suppl. 2: S279-82
36. Manfredi R, Calza L, Chiodo F. Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: a 10-year survey. J Cutan Pathol 2002 Mar; 29: 168-72
37. Goldstein AJC, Citron DM, Merriam CV, et al. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob Agents Chemother 1999 Jun; 43: 1475-9
38. Stone HH. Soft tissue infections. Am Surg 2000 Feb; 6: 162-5
39. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990 Sep; 150: 1907-12
40. Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 1989; 21: 537-42
41. Hook III EW, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986 Feb; 146: 295-7
42. Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999 Dec; 29: 1483-8
43. Lal A, Warren J, Bedrossian CWM, et al. The role of fine needle aspiration in diagnosis of infectious disease. Lab Med 2002 Nov; 33: 866-72
44. York MK. A closer look at the NCCLS guideline for rapid abbreviated identification methods. Advance 2002 Jul; 7: 23-5
45. Nichols RL, Smith JW, Geckler RW, et al. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995 Apr; 88: 397-404
46. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin structure infections in adults: results of a prospective randomized double-blind study. Clin Infect Dis 2002 Jun; 34: 1460-8
47. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000 Dec; 44: 3408-13
48. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002 Jun; 34: 1481-90
49. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized multicentre studies of quinupristin/dalfopristin versus cefazolin oxacillin or vancomycin. J Antimicrob Chemother 1999 Aug; 44: 263-73
50. Gentry LO, Rodriguez-Gomez G. Ofloxacin treatment of difficult infections of the skin and skin structure. Cutis 1993 Jan; 51: 55-8
51. Siami G, Christou N, Eiseman I, et al. Clinafloxacin versus piperacillin-tazobactam in the treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother 2001 Feb; 45: 525-31
52. Langtry HD, Lamb HM. Levofloxacin, its use in infections of the respiratory tract skin soft tissues and urinary tract. Drugs 1998 Sep; 56: 487-515
53. Nichols RL, Smith JW, Gentry LO, et al. Multicenter randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997 Dec; 90: 1193-200
54. Tarshis GA, Miskin BM, Jones TM, et al. Once daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind multicenter randomized study. Antimicrob Agents Chemother 2001 Aug; 45: 2358-62
55. Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000 Oct; 54: 497-503
56. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001 Mar; 23: 356-91
57. Fung HB, Kuczynski S, Finch DA, et al. Current issues in gram-negative resistance: extended spectrum beta-lactamases and inducible beta-lactamases. J Pharm Pract 2001 Feb; 14: 6-17
58. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance program. J Antimicrob Chemother 1999 Jun; 43: 783-92
59. Strom PR, Geheber CE, Morris ES, et al. Clinical comparison of cefotaxime versus the combination of Gentamicin plus clindamycin in the treatment of polymicrobial soft tissue surgical sepsis. Clin Ther 1982; 5 Suppl. A: 26-31
60. Hackford AW, Tally FP, Reinhold RB, et al. Prospective study comparing imipenem-cilastatin with clindamycin and Gentamicin for the treatment of serious surgical infections. Arch Surg 1988 Mar; 123: 322-6
61. Stone HH, Geheber CE, Kolb LD, et al. Clinical comparison of cefotaxime versus the combination of Gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft tissue surgical sepsis. Clin Ther 1981; 4 Suppl. A: 67-80
62. Avelox® [package insert]. West Haven (CT): Bayer Corporation Pharmaceutical Division, 2002
63. Davison AJ, Rotstein OD. The diagnosis and management of common soft tissue infections. Can J Surg 1988; 31: 333-6
64. Swartz MN. Cellulitis and subcutaneous tissue infections. In: Mandell GL, editor. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 1037-57
65. File TM, Tan JS. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infectiqons. Eur J Surg Suppl 1994; 573: 51-5
66. Brook I. Antimicrobial therapy of skin and soft tissue infection in children. J Am Podiatr Med Assoc 1993; 83: 398-405